Fred E Cohen has an estimated net worth of $48.2 Million. This is based on reported shares across multiple companies, which include Quintiles Transnational Holdings Inc., TANDEM DIABETES CARE INC, CareDx, Inc., VERACYTE, INC., Intellia Therapeutics, Inc., Progyny, Inc., BIOCRYST PHARMACEUTICALS INC, UroGen Pharma Ltd., Roka BioScience, Inc., GENOMIC HEALTH INC, FIVE PRIME THERAPEUTICS INC, and Kyverna Therapeutics, Inc..
2016 was Fred E Cohen's most active year for acquiring shares with 25 total transactions. Fred E Cohen's most active month to acquire stocks was the month of May. 2019 was Fred E Cohen's most active year for disposing of shares, totalling 20 transactions. Fred E Cohen's most active month to dispose stocks was the month of October. 2026 saw Fred E Cohen paying a total of $1,402,500.00 for 150,000 shares, this is the most they've acquired in one year. In 2020 Fred E Cohen cashed out on 66,424 shares for a total of $1,074,555.36, their largest year based on trade value.